Q-omics provides the consensus-scored C5orf60 profile across patient tissues and cancer cell-line models. C5orf60 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C5orf60 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, C5orf60 RNA expression shows 12,790 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where C5orf60 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf60 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf60 survival associations across molecular data types. C5orf60 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf60 RNA expression–survival associations across cancer types. High C5orf60 expression shows unfavorable associations in KICH, KIRC, THCA and ACC, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C5orf60 RNA expression.
This table summarizes C5orf60 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C5orf60. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf60 shows higher tumor expression in HNSC, UCEC, BRCA, LUSC, CHOL and PRAD. The HNSC box plot shows higher C5orf60 RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p < 0.001).
This table shows molecular features associated with C5orf60 in patient tissues and cancer cell lines. In patient samples, C5orf60 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf60 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY.
